Raymond James Downgrades Ascendis Pharma on Novo Nordisk Split

Raymond James downgraded Ascendis Pharma (ASND) from 'Strong Buy' to 'Outperform' while maintaining its $287 price target, following the company's decision to reacquire global rights to its metabolic and cardiovascular programs from Novo Nordisk.

The rating change marks a shift from a near-term catalyst perspective toward a longer-term development outlook for the biopharmaceutical firm, which simultaneously announced a $400 million share repurchase program alongside the partnership termination.

"While the partnership with Novo Nordisk was previously viewed as a likely catalyst for a near-term strategic outcome, the reversion of rights suggests a longer-term timeline for realizing value," Raymond James analysts noted in the rating adjustment.

Shifting From Partnered Catalysts to Internal Development

The split with Novo Nordisk returns full control of the TransCon metabolic and cardiovascular pipelines back to Ascendis Pharma. Under the previous arrangement, the collaboration with a major pharmaceutical player provided market validation and shared development costs, serving as a primary focal point for investors tracking the portfolio's near-term milestones.

By bringing the programs back in-house, Ascendis assumes direct responsibility for clinical advancement and funding. To support capital return strategies amid this structural pivot, the company initiated a $400 million share repurchase program, signaling management's confidence in its underlying balance sheet following the Investing.com report.

Pipeline Progress Highlighted by Yuviwel Data

Away from the metabolic portfolio, Ascendis recently reported clinical data for other core assets. The company released Phase 2 reACHin study results for Yuviwel in infants with achondroplasia, demonstrating an annualized growth velocity of 9.9 cm/year.

According to the clinical data, treatment with Yuviwel eliminated the need for surgical spinal decompression among trial participants, reinforcing the therapeutic profile of its proprietary TransCon technology platform even as the cardiovascular partnership dissolves.

What the Reversion Means for Shareholders

The downgrade underscores the shifting valuation mechanics for specialty biotechs when high-profile partnerships end. Without a larger corporate partner funding or co-developing the metabolic and cardiovascular assets, institutional observers like Raymond James are recalibrating timelines, pushing expected valuation inflection points further out into the clinical development cycle.